Global Antibody Drug Conjugates Market to Reach USD 50.2 Billion by 2033, Impelled by Increasing Instances of Cancer

December 18, 2024 | Healthcare

According to the latest report by IMARC Group, titled “Antibody Drug Conjugates Market Report by Component (Monoclonal Antibodies, Linker, Cytotoxic Agent, and Others), Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Application (Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others), End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, and Others), and Region 2025-2033,” the global antibody drug conjugates market reached a value of USD 9.4 Billion in 2024. Antibody drug conjugates (ADCs) refer to a class of biopharmaceutical drugs that are designed as a targeted therapy for treating cancer. They are made up of monoclonal antibodies (mAb) that chemically bind to specific receptors or proteins found on cancer cells. Upon entering the cells, the linked cytotoxic anticancer agents trigger the internalization of the antibody and allows sensitive bifurcation between healthy and diseased tissues. This, in turn, assists in enhancing the cell-killing potential of mAb, increasing drug tolerability, maximizing efficiency, and minimizing systematic exposure.

Global Antibody Drug Conjugates Market Trends:

The global ADCs market is majorly being driven by the increasing prevalence of cancer due to sedentary lifestyle and rising number of smokers. In confluence with this, the shifting individual preference toward targeted and personalized cancer treatments is further facilitating the need for ADCs across the globe. Additionally, rising healthcare expenditures, along with rapid advancements in medical technologies to engineer novel linkers with additional antibody attachments to allow the expansion of payloads are acting as other growth-inducing factor. Furthermore, manufacturers are continuously investing in research and development (R&D) activities to optimize existing chemical triggers and improve the absorption, distribution, metabolism, and excretion, which are catalyzing the market growth. Other than this, vendors are increasingly collaborating with other companies to share resources, technology, product knowledge, and expand businesses. For instance, in 2019, Shanghai Miracogen entered into an agreement with Netherlands-based Synaffix to utilize its tools and resources for building ADCs. This, in turn, is creating a positive outlook for the market. Looking forward, the market is expected to reach a value of USD 50.2 Billion by 2033, exhibiting a CAGR of 19.45% during 2025-2033.

Market Summary:

  • Based on the component, the market has been divided into monoclonal antibodies, linker, cytotoxic agent, and others.
  • On the basis of the target, the market has been classified into antibody-protein toxin, antibody-chelated radionuclide, antibody-small-molecule drug, and antibody-enzyme conjugates.
  • Based on the application, the market has been segmented into lymphoma, ovarian cancer, lung cancer, breast cancer, brain tumor, and others.
  • On the basis of the end user, the market has been divided into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, and others.
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has also been examined, with some of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.


Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Component, Target, Application, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Antibody Drug Conjugates Market to Reach USD 50.2 Billion by 2033, Impelled by Increasing Instances of Cancer
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials